Theranos

Business By Rebecca Robbins and Meghana Keshavan

Theranos plans bold expansion even as it reels from new setbacks

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: UK refuses to cover Bristol lung cancer drug

Politics By Rebecca Robbins

When does hyping a product become a criminal act? Theranos may be about to find out

Business By Rebecca Robbins

Theranos CEO Elizabeth Holmes says she’s ‘devastated’ by setbacks

Business By Rebecca Robbins

Theranos CEO Elizabeth Holmes faces possible two-year ban from blood-testing industry

First Opinion By Steve Brozak

Theranos debacle may scare investors away from diagnostic technology

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Sanofi poaches a top scientist from AstraZeneca

Politics By Ed Silverman

Avoiding ‘teapot tempest,’ Clinton campaign distances itself from Theranos

Politics By David Nather

What Theranos has to lose by hosting a Hillary Clinton fundraiser

Politics By Eric Boodman

Beleaguered Theranos CEO to hold fundraiser for Hillary Clinton

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Walgreens threatens to terminate Theranos partnership

Business By Rebecca Robbins

Is Theranos finished? Watch for these 5 telltale signs

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Roche internal investigation, problems at Theranos lab

Business By Rebecca Robbins

The Theranos scandal should be a wake-up call. Here are 4 reasons it won’t be

Business By Charles Piller

3 people to watch in Silicon Valley in 2016

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: US prices higher for top-selling drugs, FDA investigating Theranos

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Drug makers pay up for fraud, false claims